The percentage of Ki-67-positive MLA PDX tumors tended to be greater in the control group than in the carboplatin and combination therapy groups, although this difference was difficult to quantify because of differences in tumor size and tumor/stromal areas (Fig. 5C). Here, MKI67 is linked to neoplasm.